AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03237286
Drug: Intravenous ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
Trial: NCT00732537
Drug: Oxygen (>90% by hood) - standard therapy
RxNorm normalized name: oxygen 90 %
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen (\>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
Trial: NCT02094365
Drug: ALS-008176
RxNorm normalized name: ALS-008176
DrugBank: Lumicitabine (DB14808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00865280
Drug: linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
Trial: NCT00865280
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
Trial: NCT00874419
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erlotinib 150 mg oral, once a day
Trial: NCT00874419
Drug: gemcitabine/carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
Trial: NCT00056797
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00947882
Drug: Degarelix 10 mg
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg degarelix, 40 mg/mL solution
Trial: NCT00947882
Drug: Degarelix 20 mg
RxNorm normalized name: DEGARELIX 20 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FIRMAGON]
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg degarelix, 40 mg/mL solution
Trial: NCT00947882
Drug: Degarelix 30 mg
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg degarelix, 40 mg/mL solution
Trial: NCT00860548
Drug: currently available therapy in the community
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
Trial: NCT02644876
Drug: Penehyclidine inhalation
RxNorm normalized name: Penequinine, Penehyclidine
DrugBank: Penequinine, Penehyclidine (DB16287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Trial: NCT00073476
Drug: traxiprodil (CP-101,606)
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01385527
Drug: Topical Triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone to all affected areas once daily
Trial: NCT01906762
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
Trial: NCT03445663
Drug: AMG 424
RxNorm normalized name: AMG 424
DrugBank: AMG 424 (DB17357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IV infusions of AMG 424
Trial: NCT00194038
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
Trial: NCT00138866
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01575626
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices.
Trial: NCT01508806
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 0.75 mg, administered as a subcutaneous injection
Trial: NCT03181529
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
Trial: NCT03126318
Drug: COR-001
RxNorm normalized name: Aspi-Cor
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory therapy
Trial: NCT02784067
Drug: Sucraid
RxNorm normalized name: Sucraid
DrugBank: Sacrosidase (DB06760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug
Trial: NCT02211170
Drug: Lipopolysaccharide
RxNorm normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopolysaccharide (LPS) for endotoxin challenge
Trial: NCT03985969
Drug: elafibranor
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor 120mg is a coated tablet for oral administration
Trial: NCT03985969
Drug: CHRONO-INDOCID
RxNorm normalized name: Indocid
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
Trial: NCT01151904
Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
Trial: NCT01151904
Drug: latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost administered in the affected eye(s) as prescribed by physician.
Trial: NCT01311141
Drug: doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doripenem once i.v.500mg
Trial: NCT00794313
Drug: Amantadine 300 mg
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine, 300 mg, capsule, three times a day, two weeks
Trial: NCT00794313
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
Trial: NCT00794313
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill, capsule, three times a day, 2 weeks
Trial: NCT00851227
Drug: conivaptan hydrochloride
RxNorm normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT04660916
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
Trial: NCT01286896
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses.
Trial: NCT02379637
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03959397
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel monotherapy or combination therapeutic regimen
Trial: NCT00386191
Drug: clopidogrel (SR25990C)
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral administration
Trial: NCT02923557
Drug: Pirarubicin
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
Trial: NCT00823875
Drug: Cilostazol group
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
Trial: NCT00823875
Drug: Probucol group
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
Trial: NCT00823875
Drug: Cilostazol + Probucol group
RxNorm normalized name: Probucol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
Trial: NCT03795272
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2:1 randomization to receive rucaparib/placebo twice daily for 24 month
Trial: NCT00006100
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03617328
Drug: Montanide ISA-51
RxNorm normalized name: isopropyl alcohol
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
Trial: NCT03617328
Drug: polyICLC
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polyICLC, local adjuvant
Trial: NCT03617328
Drug: CDX-1127
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDX-1127, anti-CD27 monoclonal antibody
Trial: NCT01030926
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Trial: NCT01030926
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Trial: NCT01867697
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01867697
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01867697
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01867697
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01867697
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02722018
Drug: GDC-0810 Phase II Tablet
RxNorm normalized name: GDC-0810
DrugBank: GDC-0810 (DB12253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
Trial: NCT02722018
Drug: GDC-0810 Phase III Prototype Tablet
RxNorm normalized name: CARDIOTOXIN III
DrugBank: GDC-0810 (DB12253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
Trial: NCT00706342
Drug: Fostamatinib Disodium / R935788
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R935788 tablets
Trial: NCT01034670
Drug: fluorescent Peptide
RxNorm normalized name: EMI-137 (fluorescent peptide targeted against c-met)
DrugBank: EMI-137 (DB19174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microdosing; Topical through the endoscope
Trial: NCT01034670
Drug: fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mcg topical
Trial: NCT01034670
Drug: indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg topical
Trial: NCT02254954
Drug: Macitentan in combination with RT and TMZ
RxNorm normalized name: macitentan and tadalafil
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
Trial: NCT02001636
Drug: Resource Instant Protein 88
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
Trial: NCT02001636
Drug: Resource Maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
Trial: NCT04681105
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04681105
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT04681105
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02382380
Drug: Gadoterate
RxNorm normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
Trial: NCT03304938
Drug: Lavender Oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Trial: NCT01396070
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10.
Trial: NCT02657603
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injected through the new Catheter (LAX)
Trial: NCT02657603
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injected through the new Catheter (SAX)
Trial: NCT00456027
Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®)
DrugBank: rhGAD65 (DB04963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
Trial: NCT03803241
Drug: CD133+ infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of cells cd133+
Trial: NCT00695929
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT00695929
Drug: Milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT02174822
Drug: AVP-786
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02174822
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02174822
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02929407
Drug: FE 204205
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial.
Trial: NCT03418961
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01160822
Drug: Placebo to canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intra-articular injection
Trial: NCT03037580
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sustained-release oral tablets for TID administration
Trial: NCT00152269
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg Tablet, oral Daily for 12 months
Trial: NCT00152269
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg Tablet, oral Daily for 12 months
Trial: NCT00254930
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03200886
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
Trial: NCT01250418
Drug: Ketamine group
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.